Pharmstandard To Spin Off OTC Unit, Buy Singaporean Co.
Russian pharmaceutical giant Pharmstandard OAO will spin off its nonprescription drug business and acquire smaller competitor Bever Pharmaceutical Pte Ltd. for $630 million, the company announced Monday....To view the full article, register now.
Already a subscriber? Click here to view full article